19/06/2018 – AB Science expects study to be completed in 2019. Post navigationPreviousPrevious post:Update on EU marketing authorization application for masitinib in the treatment of amyotrophic lateral sclerosisNextNext post:Combined General Shareholders’ Meeting held on June 29, 2018Related PostsUpdate on the restructuring of the AB Science clinical development department in 2018December 19, 2018Masitinib phase 3 study in Alzheimer’s disease has completed patient recruitmentOctober 22, 2018Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral SclerosisOctober 8, 2018First half of 2018 revenuesOctober 1, 2018Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancerJuly 23, 2018Results of the Combined General Shareholders’ Meeting held on June 29 2018July 3, 2018
Update on the restructuring of the AB Science clinical development department in 2018December 19, 2018
Publication of a previously unknown mechanism linked to the progression of Amyotrophic Lateral SclerosisOctober 8, 2018
Positive IDMC recommendation to continue the study based on a trend analysis of the masitinib phase 2/3 study in refractory metastatic colorectal cancerJuly 23, 2018
